Gunderson Capital Management LLC Buys New Position in argenex SE $ARGX

Gunderson Capital Management LLC acquired a new position in argenex SE (NASDAQ:ARGX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,078 shares of the company’s stock, valued at approximately $5,828,000. argenex makes up approximately 1.6% of Gunderson Capital Management LLC’s investment portfolio, making the stock its 26th biggest holding.

Several other institutional investors also recently modified their holdings of ARGX. Nvwm LLC grew its holdings in argenex by 1.3% in the third quarter. Nvwm LLC now owns 1,538 shares of the company’s stock worth $1,475,000 after purchasing an additional 20 shares during the period. Mather Group LLC. increased its position in argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock valued at $78,000 after buying an additional 13 shares in the last quarter. Sanders Morris Harris LLC bought a new position in argenex during the 3rd quarter valued at approximately $1,755,000. Sivik Global Healthcare LLC purchased a new position in argenex during the third quarter valued at $1,918,000. Finally, GAMMA Investing LLC raised its stake in argenex by 31.5% during the third quarter. GAMMA Investing LLC now owns 459 shares of the company’s stock valued at $440,000 after buying an additional 110 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Price Performance

Shares of argenex stock traded up $31.20 during trading on Thursday, hitting $849.50. 211,627 shares of the company’s stock traded hands, compared to its average volume of 345,264. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75. The business has a 50-day simple moving average of $957.73 and a 200-day simple moving average of $880.07. The stock has a market capitalization of $53.15 billion, a P/E ratio of 32.61, a PEG ratio of 0.74 and a beta of 0.44.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. On average, equities analysts predict that argenex SE will post 28.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ARGX shares. Citigroup raised their price target on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Guggenheim initiated coverage on shares of argenex in a report on Tuesday, August 4th. They set a “buy” rating and a $1,185.00 price target on the stock. Wedbush reduced their price target on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. Weiss Ratings downgraded shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 23rd. Finally, Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,151.95.

About argenex

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).